Clinical and regulatory intelligence for Neuroendocrine Cancers with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Relevant assets

Boehringer →

Relevant companies

Boehringer Ingelheim →

Recent signals(1)

ClinicalAugust 6, 2026

Boehringer Ingelheim's BI 764532 Trial in Advanced Neuroendocrine Cancers Underway

Boehringer Ingelheim is conducting a trial (DAREON™-7) to evaluate the tolerability of BI 764532 combined with chemotherapy in advanced neuroendocrine cancer patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Neuroendocrine Cancers →

Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.